by Bob Yirka, Medical Xpress Close-up images and structural models of the gH/GL and gH/gL/gp42 nanoparticles from the two vaccines. Credit: Science Translational Medicine (2022). DOI: 10.1126/scitranslmed.abf3685 A team of researchers from the French health care company Sanofi, working with the National Institutes of Health and the National Cancer Institute in the U.S., has developed two new...
